Drug Class: Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) Mechanism of Action Abemaciclib inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), preventing them from promoting progression from G1 to S phase of the cell cycle. This can promote senescence, apoptosis, and reduced tumour size (1). Approved Indications Early breast cancer (1) Advanced or metastatic breast cancer (1) Mutated advanced or metastatic breast cancer (1) Dosage and administration Combination ther

Drug class: CDK4/6 inhibitor Mechanism of Action Ribociclib is an orally administered, highly selective small molecule inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6). It is approved in combination with other agents for the treatment of HR positive, HER2 negative advanced or metastatic breast cancer (1). Inside cells, CDK4/6 act as “ignition switches” for cell division. When bound to Cyclin D, they activate signaling that drives the cell cycle forward. In HR positive b